MicroRNAs Related to TACE Treatment Response: A Review of the Literature from a Radiological Point of View

Hepatocellular Carcinoma (HCC) is the sixth most common cancer in the world. Patients with intermediate stage (Barcelona Clinic Liver Cancer, B stage) hepatocellular carcinoma (HCC) have been able to benefit from TACE (transarterial chemoembolization) as a treatment option. MicroRNAs (miRNAs), i.e.,...

Descripción completa

Detalles Bibliográficos
Autores principales: Bozzato, Alessandro Marco, Martingano, Paola, Pozzi Mucelli, Roberta Antea, Cavallaro, Marco Francesco Maria, Cesarotto, Matteo, Marcello, Cristina, Tiribelli, Claudio, Pascut, Devis, Pizzolato, Riccardo, Pozzi Mucelli, Fabio, Giuffrè, Mauro, Crocè, Lory Saveria, Cova, Maria Assunta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8871153/
https://www.ncbi.nlm.nih.gov/pubmed/35204465
http://dx.doi.org/10.3390/diagnostics12020374
Descripción
Sumario:Hepatocellular Carcinoma (HCC) is the sixth most common cancer in the world. Patients with intermediate stage (Barcelona Clinic Liver Cancer, B stage) hepatocellular carcinoma (HCC) have been able to benefit from TACE (transarterial chemoembolization) as a treatment option. MicroRNAs (miRNAs), i.e., a subclass of non-coding RNAs (ncRNAs), participate in post-transcriptional gene regulation processes and miRNA dysfunction has been associated with apoptosis resistance, cellular proliferation, tumor genesis, and progression. Only a few studies have investigated the role of miRNAs as biomarkers predicting TACE treatment response in HCC. Here, we review the studies’ characteristics from a radiological point of view, also correlating data with radiological images chosen from the cases of our institution.

Ejemplares similares